undefined undefined
NaN.000
NaN.00%
In the Phase 3 BRUIN CLL-313 study, treatment with pirtobrutinib demonstrated a highly statistically significant and clinically meaningful improvement in progression-free survival versus bendamustine plus rituximab,
09-08 18:47
AstraZeneca (($AZN)), Abbvie (($ABBV)) announced an update on their ongoing cli...
09-08 00:58
BeOne Medicines reported positive Phase 1/2 results for sonrotoclax in relapsed or refractory mantle cell lymphoma, with regulatory submissions underway and a Phase 3 trial in progress.
08-29 22:16
中金发布研报称,维持亚盛医药-B(06855)2025年/2026年归母净利润预测不变,维持跑赢行业评级,考虑到GLORA-4进展,新适应症空间可见度提升...
08-25 12:09
截至2025年8月21日09:47,恒生医疗保健指数(HSHCI)强势上涨1.86%,成分股平安好医生(01833)上涨7.69%,丽珠医药(01...
08-21 09:53
亚盛医药-B(06855)早盘高开,股价上涨9.23%,现报94.05港元,创历史新高,成交额1.802亿港元。 亚盛医药公告,公司自主研发的Bcl-2选择...
08-18 09:43
Eli Lilly delivered a strong Q2 2025 with 38% revenue growth and major clinical milestones, despite a selloff over obesity drug trial data.
08-08 01:44
BeOne Medicines Ltd. press release (OTCPK:BEIGF): Q2 Non-GAAP EPS of ADS2.25. Revenue of ADS1.3B. More on BeiGene BeOne Medicines: Competitive Advantage Of Zanubrutinib In The CLL Field BeiGene, Ltd...
08-06 19:58
8月6日,迪哲医药(688192)公告称,近日,公司在研产品DZD8586获美国食品药品监督管理局授予“快速通道认定”(“Fast Track Designation”)用于既往接受过至少两线治疗(包括布鲁顿氏酪氨酸激酶(BTK)抑制剂和BCL-2抑制剂)的复发难治性慢性淋巴细胞白血病/小淋巴细胞淋巴瘤(CLL/SLL)。
08-06 19:15